...
首页> 外文期刊>Infection and immunity >Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax
【24h】

Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax

机译:被杀死但具有代谢活性的炭疽芽孢杆菌疫苗可诱导广泛而具保护性的抗炭疽免疫

获取原文
           

摘要

Bacillus anthracis is the causative agent of anthrax. We have developed a novel whole-bacterial-cell anthrax vaccine utilizing B. anthracis that is killed but metabolically active (KBMA). Vaccine strains that are asporogenic and nucleotide excision repair deficient were engineered by deleting the spoIIE and uvrAB genes, rendering B. anthracis extremely sensitive to photochemical inactivation with S-59 psoralen and UV light. We also introduced point mutations into the lef and cya genes, which allowed inactive but immunogenic toxins to be produced. Photochemically inactivated vaccine strains maintained a high degree of metabolic activity and secreted protective antigen (PA), lethal factor, and edema factor. KBMA B. anthracis vaccines were avirulent in mice and induced less injection site inflammation than recombinant PA adsorbed to aluminum hydroxide gel. KBMA B. anthracis-vaccinated animals produced antibodies against numerous anthrax antigens, including high levels of anti-PA and toxin-neutralizing antibodies. Vaccination with KBMA B. anthracis fully protected mice against challenge with lethal doses of toxinogenic unencapsulated Sterne 7702 spores and rabbits against challenge with lethal pneumonic doses of fully virulent Ames strain spores. Guinea pigs vaccinated with KBMA B. anthracis were partially protected against lethal Ames spore challenge, which was comparable to vaccination with the licensed vaccine anthrax vaccine adsorbed. These data demonstrate that KBMA anthrax vaccines are well tolerated and elicit potent protective immune responses. The use of KBMA vaccines may be broadly applicable to bacterial pathogens, especially those for which the correlates of protective immunity are unknown.
机译:炭疽杆菌是炭疽的病原体。我们开发了一种新型的利用 B的全细菌细胞炭疽疫苗。被杀死但具有代谢活性的炭疽(KBMA)。通过删除 spoIIE uvrAB 基因,构建了 B基因,从而工程改造了具有产孢子和核苷酸切除修复缺陷的疫苗株。炭疽菌对S-59补骨脂素和紫外线对光化学灭活非常敏感。我们还向 lef cya 基因中引入了点突变,从而可以产生无活性但具有免疫原性的毒素。光化学灭活的疫苗株保持高度的代谢活性,并分泌保护性抗原(PA),致死因子和水肿因子。 KBMA B。炭疽疫苗对小鼠无毒,与注射到氢氧化铝凝胶上的重组PA相比,注射部位发炎少。 KBMA B。接种炭疽疫苗的动物产生了针对多种炭疽抗原的抗体,包括高水平的抗PA和毒素中和抗体。用KBMA B接种。炭疽可以完全保护小鼠免受致死剂量的无毒素Sterne 7702孢子的攻击,而兔子免受致死性肺炎剂量的全毒Ames菌株孢子的攻击。用KBMA B疫苗接种的豚鼠。炭疽被部分保护免受致命的Ames孢子攻击,这与使用许可的吸附炭疽疫苗进行的疫苗接种相当。这些数据表明,KBMA炭疽疫苗具有良好的耐受性,并引起有效的保护性免疫应答。 KBMA疫苗的使用可能广泛适用于细菌病原体,尤其是那些保护性免疫相关性未知的病原体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号